Free tool
FAERS Monitor: Zolymbus
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217307 or its brand name (Zolymbus, Bimatoprost). Reports on generic versions are filed under their own applications.
Reports
2,298
Serious
1,551
67% of reports
Hospitalization
667
Death reported
127
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective250
- ocular hyperaemia88
- eye irritation81
- nausea79
- dyspnoea78
- diarrhoea71
- fatigue71
- eye pain66
- headache63
- madarosis61
- dizziness56
- rash56
- off label use55
- fall53
- intraocular pressure increased53
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 4 |
| 2006 | 8 |
| 2007 | 12 |
| 2008 | 21 |
| 2009 | 22 |
| 2010 | 23 |
| 2011 | 36 |
| 2012 | 21 |
| 2013 | 51 |
| 2014 | 65 |
| 2015 | 82 |
| 2016 | 119 |
| 2017 | 207 |
| 2018 | 180 |
| 2019 | 198 |
| 2020 | 189 |
| 2021 | 184 |
| 2022 | 151 |
| 2023 | 219 |
| 2024 | 178 |
| 2025 | 167 |
| 2026 | 151 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,861 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| madarosisSignal | 61 | 48.3 | 37.7 | 2,768 |
| intraocular pressure increasedSignal | 53 | 38.1 | 29.2 | 1,872 |
| ocular hyperaemiaSignal | 88 | 17.0 | 13.8 | 1,310 |
| eye irritationSignal | 81 | 12.9 | 10.4 | 878 |
| eye painSignal | 66 | 10.7 | 8.4 | 573 |
| drug ineffective | 250 | 1.7 | 1.5 | 82 |
| fall | 53 | 1.5 | 1.1 | 7 |
| dyspnoea | 78 | 1.3 | 1.0 | 4 |
| rash | 56 | 1.2 | 0.9 | 1 |
| dizziness | 56 | 1.0 | 0.8 | 0 |
| diarrhoea | 71 | 1.0 | 0.8 | 0 |
| headache | 63 | 0.9 | 0.7 | 0 |
| nausea | 79 | 0.9 | 0.7 | 1 |
| fatigue | 71 | 0.8 | 0.7 | 2 |
| off label use | 55 | 0.6 | 0.4 | 18 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.